

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-44. Canceled

1 ~~45~~. (Currently amended) A method of treating metastatic ~~clinically manifest~~ mammary tumors in postmenopausal women, comprising the steps of:

- a) detecting a metastatic ~~clinically manifest~~ mammary tumor in a postmenopausal woman;
- b) administering to the postmenopausal woman a first dose of hCG; and
- c) administering to the postmenopausal woman one or more subsequent doses of hCG, wherein the first dose and the subsequent doses of hCG are administered in an amount and over a period of time effective to inhibit proliferation of mammary tumor cells, thereby treating the metastatic ~~clinically manifest~~ mammary tumors.

46-62. Canceled.

2 ~~63~~. (Currently amended) The method of claim ~~45~~¹, combined with at least one other treatment for metastatic ~~clinically manifest~~ mammary tumors.

3 ~~64~~. (Previously presented) The method of claim ~~63~~², wherein the at least one other treatment is surgery or chemotherapy.

4 ~~65~~. (Previously presented) The method of claim ~~45~~¹, wherein the mammary tumors comprise cells that are estrogen receptor-positive.

66-69. Canceled.

5 ~~70~~. (Previously presented) The method of claim ~~45~~¹, wherein the hCG is administered in an amount of 100 to 20,000 IU per day.

⁶ 71. (Previously presented) The method of claim ¹43, wherein the hCG is administered in amount of 50 to 50,000 micrograms per day.

⁷ 72. (Previously presented) The method of claim ⁶71, wherein the hCG is administered in an amount of 250 to 3,000 micrograms per day.

⁸ 73. (Previously presented) The method of claim ¹43, wherein the one or more subsequent doses of hCG are administered every second day following administration of the first dose.

⁹ 74. (Previously presented) The method of claim ¹43, wherein the one or more subsequent doses of hCG are administered three times each week following administration of the first dose.

¹⁰ 75. (Previously presented) The method of claim ¹43, wherein the one or more subsequent doses of hCG are administered for several weeks following administration of the first dose.

¹¹ 76. (Previously presented) The method of claim ¹⁰75, wherein the hCG is administered for at least 12 weeks.

¹² 77. (Previously presented) The method of claim ¹43, wherein the hCG is administered subcutaneously.

¹³ 78. (Previously presented) The method of claim ¹43, wherein the hCG is administered in combination with Type 1 interferon.

79. Canceled.

DOCKET NO.: 46598-5005-US-01 (99-01; WO/386)
Application No.: 09/868,196
Office Action Dated: July 28, 2005

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

~~14~~ 80. (Previously presented) The method of claim ~~45~~, wherein the hCG is recombinant hCG.

81-103. Canceled.